-
Neuropathic Pain: U.S. Payer and Prescriber Attitudes Toward Recently Approved and Emerging Therapies—Implications for Market Access
U.S. Physician and Payer Forum, May, 2013
Neuropathic pain (NP) is a prominent form of pain associated
with a variety of diseases and conditions, including cancer, diabetes, herpes
zoster, chronic...
-
Global: Market Access Tracker
Market Access Tracker Program, 2013
Last Updated 22 May 2013
Decision Resources’ Market
Access Tracker service explains the challenges and opportunities to
gaining—and...
-
Ovarian Cancer (Platinum-Resistant Advanced)
DecisionBase, May, 2013
Are Emerging Targeted Therapies Poised to Fill the
Significant Unmet Need for This Difficult-to-Treat Patient Population?
In 2011, more than...
-
WEBINAR: Highlights from the 11th Annual EGA Biosimilars Symposium
Past Webinars and Presentations, May, 2013
PowerPoint slides from the Decision Resources/BioTrends webinar series.
-
Argentina: Market Access Tracker
Market Access Tracker Program, 2013
Last Updated 15 May 2013
Argentina,
the fourth-largest pharmaceutical market in Latin America, and one of the
fastest-growing markets in the...
-
Migraine (Event Driven)
Pharmacor, 2013
Last Updated 13 May 2013
All the currently
available triptan products, which constituted 70% of the migraine major-market
sales in 2011, will face...
-
Chronic Obstructive Pulmonary Disease
DecisionBase, May, 2013
What Gains in Efficacy Will Be Necessary to Meet
Pulmonologist and Payer Expectations for Emerging LABA/LAMAs, LABA/ICSs, and
MABAs?
Chronic...
-
Breast Cancer (Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic)
DecisionBase, May, 2013
What Attributes Will Distinguish Emerging Therapies in
the Eyes of Oncologists and Payers?
Representing more than 50% of diagnosed incident...
-
Migraine: Evolving U.S. Market Access and Clinical Practice in the Era of Generic Triptans, Innovative Reformulations, and Botox
U.S. Physician and Payer Forum, May, 2013
For the estimated 35 million people in the United States who
suffer from migraines, an array of prescription therapies are available to
provide acute treatment...
-
Industry Opportunity Platform: PatientBase
PatientBase: Mature and Emerging Markets, May, 2012
PatientBase is the premier epidemiology database that provides robust coverage of more than 120 disease indications and more than 2300 patient populations....
-
Industry Opportunity Platform: Pharmaview
Pharmaview, May, 2012
Pharmaview offers all the insight you need to understand how the leading players in the biopharmaceutical industry function.
Company strategies,...
-
Pancreatic Cancer
Pharmacor, May, 2013
Pancreatic cancer is characterized by a very poor prognosis;
five-year relative survival is 5%. The disease’s rapid progression, most
patients’ poor...
-
WEBINAR: Renal Anemia in Chronic
Kidney Disease (CKD): Following the Omontys Recall
Past Webinars and Presentations, April, 2013
PowerPoint slides from the Decision Resources webinar series.
-
Multiple Myeloma (Relapsed/Refractory)
DecisionBase, April, 2013
As Carfilzomib and Pomalidomide Make Inroads into the
Market, What Key Attributes Will Differentiate Emerging Therapies According to
Hematological...
-
Hepatitis C Virus
DecisionBase, April, 2013
Substantial Opportunity and Fierce Competition Await
Developers of Interferon-Free Therapies for Treatment-Naive Patients
Affecting at least 170...
-
Positioning of Current and Emerging Agents for Hepatitis C Virus: Physician and Payer Perspectives on the Prescribing and Patient Access Landscape in Brazil, Mexico, and Argentina
Emerging Markets Physician and Payer Forum, April, 2013
Increases
in seroprevalence cases of hepatitis C virus (HCV), disease awareness, and
patient access to HCV treatment create significant market opportunity in...
-
Alcohol Addiction
DecisionBase, April, 2013
How Would a Harm Reduction Treatment Paradigm Be
Received by Physicians?
As a result of low diagnosis and drug-treatment rates, the
market for...
-
Turkey: Market Access Tracker
Market Access Tracker Program, 2013
Last Updated 24 April 2013
The Turkish pharmaceutical
market is the 6th largest in Europe and the 16th largest in the world and
experienced rapid...
-
Obesity (Event Driven)
Pharmacor, 2013
Last Updated 23 April 2013
Obesity continues to be one of the fastest growing disorders
worldwide, and the costs of treating obesity-related...
-
Parkinson's Disease (Event Driven)
Pharmacor, 2013
Last Updated 23 April 2013
Parkinson’s disease (PD) is one of the most common chronic
neurodegenerative diseases in the elderly, and its prevalence...